Tumor-infiltrating lymphocytes predict efficacy of immunotherapy in advanced non-small cell lung cancer: a single-center retrospective cohort study

References

• Mamdani H, Matosevic S, Khalid AB, et al. Immunotherapy in lung cancer: current landscape and future directions. Front Immunol. 2022;13:823618. doi: 10.3389/fimmu.2022.823618.
   PubMed Web of Science ®Google Scholar
• Melosky B, Juergens R, Hirsh V, et al. Amplifying outcomes: checkpoint inhibitor combinations in first-line non-small cell lung cancer. Oncologist. 2020;25(1):64–77. doi: 10.1634/theoncologist.2019-0027.
   PubMed Web of Science ®Google Scholar
• Qiao M, Jiang T, Ren S, et al. Combination strategies on the basis of immune checkpoint inhibitors in non-small-cell lung cancer: where do we stand? Clin Lung Cancer. 2018;19(1):1–11. doi: 10.1016/j.cllc.2017.06.005.
   PubMed Web of Science ®Google Scholar
• Badalamenti G, Fanale D, Incorvaia L, et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone? Cell Immunol. 2019;343:103753. doi: 10.1016/j.cellimm.2018.01.013.
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Gonzalez-Cao M, Crespo G, et al. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther Adv Med Oncol. 2018;10:1758834017749748. doi: 10.1177/1758834017749748.
   Web of Science ®Google Scholar
• Mazzaschi G, Madeddu D, Falco A, et al. Low PD-1 expression in cytotoxic CD8(+) tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value. Clin Cancer Res. 2018;24(2):407–419. doi: 10.1158/1078-0432.Ccr-17-2156.
   PubMed Web of Science ®Google Scholar
• Remon J, Facchinetti F, Besse B. The efficacy of immune checkpoint inhibitors in thoracic malignancies. Eur Respir Rev. 2021; 30(162):200387. doi: 10.1183/16000617.0387-2020.
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, et al. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–173. doi: 10.1016/j.ccell.2020.10.001.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016; 17(12):e542–e551. doi: 10.1016/s1470-2045(16)30406-5.
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. doi: 10.1093/annonc/mdy495.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen Y, Wang H, et al. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. J Immunother Cancer. 2021;9(6):e002356. doi: 10.1136/jitc-2021-002356.
   PubMed Web of Science ®Google Scholar
• Pang Z, Chen X, Wang Y, et al. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: development and validation of an individualized prognostic model. Int Immunopharmacol. 2020;86:106744. doi: 10.1016/j.intimp.2020.106744.
   PubMed Web of Science ®Google Scholar
• Ameratunga M, Asadi K, Lin X, et al. PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC. PLOS One. 2016;11(4):e0153954. doi: 10.1371/journal.pone.0153954.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Lisberg A, Zaretsky JM, et al. Tumor characteristics associated with benefit from pembrolizumab in advanced non-small cell lung cancer. Clin Cancer Res. 2019;25(16):5061–5068. doi: 10.1158/1078-0432.Ccr-18-4275.
   PubMed Web of Science ®Google Scholar
• Zhang F, Bai H, Gao R, et al. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer. Cancer Immunol Immunother. 2020;69(12):2599–2611. doi: 10.1007/s00262-020-02642-4.
   PubMed Web of Science ®Google Scholar
• Bie F, Tian H, Sun N, et al. Research progress of anti-PD-1/PD-L1 immunotherapy related mechanisms and predictive biomarkers in NSCLC. Front Oncol. 2022;12:769124. doi: 10.3389/fonc.2022.769124.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zeng D, Ou Q, et al. Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis. JAMA Netw Open. 2019;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
   PubMed Web of Science ®Google Scholar
• Durgeau A, Virk Y, Corgnac S, et al. Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. Front Immunol. 2018;9:14. doi: 10.3389/fimmu.2018.00014.
   PubMed Web of Science ®Google Scholar
• González-Navajas JM, Elkord E, Lee J. Editorial: CD4(+) T cells in cancer immunotherapies. Front Immunol. 2021;12:737615. doi: 10.3389/fimmu.2021.737615.
   PubMed Web of Science ®Google Scholar
• Oja AE, Piet B, van der Zwan D, et al. Functional heterogeneity of CD4(+) tumor-infiltrating lymphocytes with a resident memory phenotype in NSCLC. Front Immunol. 2018;9:2654. doi: 10.3389/fimmu.2018.02654.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–2940. doi: 10.1172/jci91190.
   PubMed Web of Science ®Google Scholar
• Frafjord A, Buer L, Hammarström C, et al. The immune landscape of human primary lung tumors is Th2 skewed. Front Immunol. 2021;12:764596. doi: 10.3389/fimmu.2021.764596.
   PubMed Web of Science ®Google Scholar
• Gao S, Hsu TW, Li MO. Immunity beyond cancer cells: perspective from tumor tissue. Trends Cancer. 2021; 7(11):1010–1019. doi: 10.1016/j.trecan.2021.06.007.
   PubMed Web of Science ®Google Scholar
• Ganesan AP, Johansson M, Ruffell B, et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol. 2013;191(4):2009–2017. doi: 10.4049/jimmunol.1301317.
   PubMed Web of Science ®Google Scholar
• Hu X, Gu Y, Zhao S, et al. Elevated circulating CD4(+)CD25(-)Foxp3(+) regulatory T cells in patients with nonsmall cell lung cancer. Cancer Biother Radiopharm. 2019;34(5):325–333. doi: 10.1089/cbr.2018.2672.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. FOXP3+ treg as a therapeutic target for promoting anti-tumor immunity. Expert Opin Ther Targets. 2018; 22(4):353–363. doi: 10.1080/14728222.2018.1451514.
   PubMed Web of Science ®Google Scholar
• Alemohammad H, Najafzadeh B, Asadzadeh Z, et al. The importance of immune checkpoints in immune monitoring: a future paradigm shift in the treatment of cancer. Biomed Pharmacother. 2022;146:112516. doi: 10.1016/j.biopha.2021.112516.
   PubMed Web of Science ®Google Scholar